192 related articles for article (PubMed ID: 35366156)
21. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
24. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
[TBL] [Abstract][Full Text] [Related]
25. Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.
Bulutay P; Eren ÖC; Özen Ö; Haberal AN; Kapucuoğlu N
Turk J Obstet Gynecol; 2023 Sep; 20(3):164-173. PubMed ID: 37667475
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
28. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.
Ye S; Zhou S; Zhong S; Shan B; Jiang W; Yang W; Cai X; Yang H
BMC Cancer; 2022 Apr; 22(1):449. PubMed ID: 35461222
[TBL] [Abstract][Full Text] [Related]
29. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
30. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
[TBL] [Abstract][Full Text] [Related]
31. Detection of DNA Mismatch Repair Protein Abnormalities in Sudanese Colorectal Cancer Patients Using Immunohistochemical Methods.
Zakout YM; Lanza G
J Gastrointest Cancer; 2019 Sep; 50(3):530-536. PubMed ID: 29850986
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
[TBL] [Abstract][Full Text] [Related]
33. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
34. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
[TBL] [Abstract][Full Text] [Related]
35. Expression of PD-1 in Tumor Cells is Associated with Shorter Survival in Non-metastatic Intestinal-type Gastric Adenocarcinoma.
Namvar N; Montazer M; Ahmadvand S; Sadeghian B; Ghaderi A
Iran J Allergy Asthma Immunol; 2022 Dec; 21(6):600-615. PubMed ID: 36640052
[TBL] [Abstract][Full Text] [Related]
36. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
[TBL] [Abstract][Full Text] [Related]
37. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
38. Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients.
Ren XY; Song Y; Wang J; Chen LY; Pang JY; Zhou LR; Shen SJ; Cao X; Wang YX; Shao MM; Liang ZY; Sun Q; Wu HW
Front Oncol; 2021; 11():570623. PubMed ID: 33747906
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
[TBL] [Abstract][Full Text] [Related]
40. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers.
Kato M; Takano M; Miyamoto M; Sasaki N; Goto T; Tsuda H; Furuya K
J Gynecol Oncol; 2015 Jan; 26(1):40-5. PubMed ID: 25310854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
